Previous Article | Next Article 
Journal of Clinical Microbiology, December 1998, p. 3585-3589, Vol. 36, No. 12
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Standardization of the Human Cytomegalovirus Antigenemia
Assay by Means of In Vitro-Generated pp65-Positive Peripheral
Blood Polymorphonuclear Leukocytes
Giuseppe
Gerna,*
Elena
Percivalle,
Maria
Torsellini, and
M. Grazia
Revello
Servizio di Virologia, Istituto di Ricovero e
Cura a Carattere Scientifico Policlinico S. Matteo, 27100 Pavia, Italy
Received 19 June 1998/Returned for modification 13 August
1998/Accepted 17 September 1998
 |
ABSTRACT |
We generated in vitro human cytomegalovirus (HCMV) pp65-positive
polymorphonuclear leukocytes (PMN) resembling those detected in vivo,
following cocultivation of PMN from healthy donors and wild-type
HCMV-infected endothelial cells or fibroblasts. After purification, PMN
are suitable for preparation of cytospots which can be used for the
antigenemia assay. Cytospin preparations containing a predetermined
number of in vitro-generated pp65-positive PMN were used to test some
of the major parameters involved in performing the antigenemia assay.
The results showed or confirmed that (i) formalin fixation followed by
permeabilization is the best fixation procedure developed to date, (ii)
the test performance levels provided by different pools of
pp65-specific monoclonal antibodies may be significantly different, and
(iii) long-term storage (for an unlimited time) is best achieved by
keeping fixed slides at
80°C, whereas short-term storage (for up to
1 month) is best achieved by keeping unfixed slides at room
temperature. This finding signifies that slides can be shipped all over
the world at room temperature. In conclusion, the newly developed
procedure for in vitro generation of pp65-positive PMN will provide the
basis for standardization of the HCMV antigenemia assay and development of quality control programs.
 |
INTRODUCTION |
Since its introduction in 1988 (13, 14), the procedure for antigenemia assay for detection
of pp65 of human cytomegalovirus (HCMV) in polymorphonuclear leukocytes
(PMN) has undergone multiple modifications and improvements of cell
fixation, immunostaining procedure, and use of pooled monoclonal
antibodies (3). However, standardization has not been
achieved thus far, and results obtained in different laboratories are
difficult to compare. The major obstacle to the standardization of the
antigenemia assay has been the lack of biological material
(pp65-positive PMN) available in unlimited quantities and standardized
with a predetermined ratio of pp65-positive PMN/pp65-negative PMN. Thus
far, the only positive control introduced into a commercially available
kit for determination of pp65-antigenemia (5) consisted of
cytospin preparations containing insect cells expressing HCMV pp65
mixed with PMN from healthy volunteers (12).
In the present report, we describe the use of the recently developed
procedure for generating in vitro pp65-positive PMN (9) for
the optimization and standardization of the HCMV antigenemia assay. The
availability of a proper positive control can lead to development of
standardization protocols and quality control programs in the near future.
 |
MATERIALS AND METHODS |
Isolation of PMN.
Concentrated preparations of human PMN
from either HCMV-seropositive or HCMV-seronegative healthy donors were
obtained as follows. One milliliter of 6% dextran solution (molecular
weight, 70,000) in saline was added to 5.0 ml of heparinized blood.
Following incubation at 37°C for 30 min, the supernatant was
dispensed onto Ficoll-Hypaque and centrifuged at 600 × g for 35 min. Contaminating erythrocytes were removed by
hypotonic lysis (1.0 ml of 0.8% NH4Cl for 2 min). Both the
purity and the viability of harvested PMN were consistently found to be
>95%, as assessed by May-Grünwald staining and trypan blue
exclusion, respectively (9).
Cocultivation of PMN and cell cultures infected with different
HCMV strains.
PMN were then cocultivated with HCMV-infected human
umbilical vein endothelial cells (HUVEC) or human embryonic lung
fibroblasts (HELF). HUVEC were obtained by trypsin treatment of
umbilical cord veins and used at passages 5 to 10, while HELF were
derived from a cell strain developed in our laboratory and used at
passages 20 to 30. HCMV strains, either laboratory-adapted (AD169,
Davis, and Towne from the American Type Culture Collection, Rockville, Md.) or wild-type (HCMV isolates from blood and different body sites)
strains, were routinely propagated in HELF cultures. In addition, one
wild-type strain (VR6110) was adapted to growth on HUVEC. Cocultivation
of PMN and HCMV-infected HELF or HUVEC (ratio, 2:1 to 5:1) was
continued for 24 h at 37°C.
pp65-positive PMN detection and purification.
Following
cocultivation, pp65-positive HELF or HUVEC were easily distinguishable
from pp65-positive PMN by their size and predominantly cytoplasmic
staining in contrast to the restricted PMN nuclear staining
(3). However, in order to separate PMN from infected cells,
cell mixtures (5 × 105 to 1 × 106
cells) in 250 µl of RPMI 1640 (Flow Laboratories, Irvine, Scotland) plus 1% fetal calf serum were placed in the upper compartment of a
cell culture insert (5-µm-pore-size, 6.5-mm-diameter Transwell filters; Costar, Cambridge, Mass.) and incubated for 3 h at 37°C in a 5% CO2 humidified atmosphere, while the bottom
compartment contained 10
8 M
formyl-methionyl-leucyl-phenylalanine (Sigma Chemical Co., St. Louis,
Mo.) in 500 µl of RPMI 1640 plus 1% fetal calf serum (9,
11). After incubation, chambers were shaken to dislodge PMN from
the lower surface of the inserts. PMN were then collected, washed,
counted, and used for cytospins preparation. In preliminary experiments, PMN collected after migration were further purified by
fluorescence-activated cell sorting (FACS) following PMN staining with
CD66b (Immunotech, Milan, Italy). The number of pp65-positive PMN was
determined on aliquots of migrated PMN before and after FACS purification.
Standardization of the antigenemia assay with in vitro-generated
pp65-positive PMN.
Using in vitro-generated pp65-positive PMN, we
addressed the problem of the standardization of the antigenemia assay
in its three basic parameters: (i) fixation, (ii) immunostaining
technique, and (iii) pool of monoclonal antibodies. The two types of
fixation most commonly used, methanol-acetone (13) and
formalin plus Nonidet P-40 (NP-40) (3), were compared. In
addition, the two most commonly used immunostaining techniques, the
immunoperoxidase (either the indirect method [immunoperoxidase assay;
IPA] or the avidin-biotin complex method [ABC]) and the
immunofluorescence assay (IFA) method (3), were compared.
Finally, once the most efficient fixation and immunostaining methods
were selected, the most commonly used pools of pp65-specific monoclonal
antibodies were compared. These were (i) our pool (referred to as PV
pool) including the three monoclonal antibodies 1C3, 2A6, and 4C1
(3), (ii) Clonab CMV (Biotest AG, Dreieich, Germany
[4]), (iii) CINApool (Argene Biosoft, Varilhes,
France), and (iv) Chemicon (Chemicon International Inc., Temecula,
Calif.). Furthermore, the optimal storage temperature for either fixed
or unfixed cytospots was investigated in view of performing quality
control programs requiring shipment of known positive controls. In each
set of experiments the following parameters were determined: (i) the number of pp65-positive PMN per 2 × 105 PMN used for
preparation of each cytospot, and (ii) the degree (intensity) of
staining, which was determined by classifying positive cells into the
three staining categories of weak (1+), moderate (2+ or 3+), and strong
(4+).
Statistical analysis.
Comparison between means was performed
with the Student t test, whereas the difference in
distribution of staining categories was analyzed by the Pearson
chi-square test.
 |
RESULTS |
In vitro generation of pp65-positive PMN.
Initial attempts at
generating pp65-positive PMN following coculture with HELF infected
with the reference HCMV strain AD169 were consistently unsuccessful.
Similarly negative results were obtained when other
laboratory-adapted strains, such as Davis or Towne, were used.
pp65-positive PMN were generated when PMN were cocultured with HUVEC
infected with a clinical HCMV isolate from blood (VR6110) (Fig.
1). Similar results were also achieved with HELF infected with different isolates from different body sites of
both immunocompromised subjects and immunocompetent subjects. No
pp65-positive PMN were observed when contact of PMN with infected cells
was prevented by using Transwell inserts (0.4-µm-pore-size membranes)
or when contact was restricted to infectious cell-free wild-type virus.

View larger version (61K):
[in this window]
[in a new window]
|
FIG. 1.
Indirect immunofluorescence (A and B) and
immunoperoxidase (C) staining of cytospin preparations of PMN
containing pp65-positive cells obtained from an AIDS patient with
disseminated HCMV infection (A) or generated in vitro (B and C). Degree
of staining is indicated as weak (w), moderate (m), or strong (s)
according to intensity of fluorescence. Magnification, ×910.
|
|
PMN purification and testing.
Once generated, pp65-positive
PMN had to be separated from contaminating HCMV-infected cells. Since
the level of purification achieved after Transwell insert migration was
not substantially increased by the additional FACS purification,
Transwell migration was subsequently used as a routine purification
step. Then, serial concentrations of pp65-positive PMN were obtained in
cytospots set up following preparation of serial mixtures, at a
different proportion, of a known pp65-positive migrated PMN suspension
and a PMN suspension from healthy donors. Results of testing of
replicate cytospin preparations containing a different number of
pp65-positive PMN are reported in Table
1, where the coefficient of variability of the mean is consistently below 10% when levels of antigenemia are
>50, while it becomes progressively higher with antigenemia levels
approaching 1.
View this table:
[in this window]
[in a new window]
|
TABLE 1.
Variability in the frequency of pp65-positive PMN in
replicates of cytospin preparations containing serial proportions of
positive and negative PMN obtained by using the PV pool
|
|
Fixation.
The better performance of the formalin plus NP-40
fixation over the methanol-acetone method was confirmed in terms of
both number of pp65-positive PMN and staining intensity (data not
shown). In addition, some experiments were carried out to verify
whether NP-40 permeabilization of PMN previously fixed with formalin
was a critical step. It was found that, although the fluorescent
staining was more evenly distributed over the entire nucleus of
positive cells in permeabilized PMN preparations, both the number of
positive cells and the degree of staining were not significantly
different in the two groups of cytospin preparations (data not shown).
Immunostaining technique.
No significant differences were
found among IFA, IPA, and ABC (Table 2).
In addition, although the distributions of different PMN staining
groups were not significantly different among the three tested
techniques, the absolute number of PMN belonging to the weak IFA
staining group was greater than the relevant IPA and ABC group values,
whereas the number of strongly stained cells was slightly lower for the
IFA technique.
View this table:
[in this window]
[in a new window]
|
TABLE 2.
Sensitivities of different immunostaining techniques with
formalin plus NP-40 as fixative (prior to storage at 80°C) and
the PV pool
|
|
Pool of monoclonal antibodies.
The results of the comparison
between the sensitivity of our pool (referred to as PV pool) containing
three monoclonal antibodies and the sensitivities of three commercially
available pools, each containing two monoclonal antibodies, are
reported in Table 3. The PV pool resulted
in significantly higher number of positive PMN than the Argene
(P = 0.0041), the Biotest (P < 0.00001), and the Chemicon (P = 0.0008) pools. In
addition, the Argene pool gave significantly better results than the
Biotest pool (P = 0.0047), whereas no statistically
significant difference was found between the Argene and Chemicon or
between the Biotest and Chemicon pools. As for distribution of staining
intensity, the PV pool gave 25% weakly, 64% moderately, and 11%
strongly stained cells, whereas the Argene, Chemicon, and Biotest pools
detected a higher percentage of weakly stained cells (38 to 43%) and
lower proportions of moderately (52 to 54%) and strongly (3 to 10%)
stained cells. However, these differences were not statistically
significant.
View this table:
[in this window]
[in a new window]
|
TABLE 3.
Sensitivities of different pools of HCMV pp65-specific
monoclonal antibodies with formalin plus NP-40 as fixative (prior
to storage at 80°C) and IFA as immunostaining technique
|
|
Storage temperature.
The optimal storage temperature was a
major issue addressed by this study. Initially, fixed and unfixed
slides were tested in parallel following a 7-day storage period at room
temperature or at
80°C (Table 4). It
was found that fixation prior to storage at
80°C gave significantly
better results than fixation after storage at
80°C and prior to
staining (P = 0.0186). In contrast, fixation prior to
staining and following storage at room temperature was by far better
than fixation done just after cytospin preparation (P = 0.0009). In other words, the best condition was a 7-day storage of
unfixed slides at room temperature followed by storage at
80°C of
fixed slides. No significant difference was found between the two
conditions. Significantly lower sensitivities were found for either
unfixed slides at
80°C or fixed slides at room temperature. In
terms of staining intensity, there was a significant difference among
the different experimental conditions tested (P = 0.0016): a significant difference was found between unfixed and
fixed slides stored at room temperature (P = 0.012),
between unfixed slides stored at room temperature and at
80°C
(P = 0.004), and between fixed and unfixed slides
stored at
80°C (P = 0.005). In general, a 7-day
storage of unfixed slides at room temperature was associated with a
relatively smaller number of weakly stained cells and a relatively
greater number of moderately stained PMN (Table 4) compared to the
other experimental conditions.
View this table:
[in this window]
[in a new window]
|
TABLE 4.
Effect of temperature during storage for a 7-day period
on fixed and unfixed PMN slides with IFA and the PV pool
|
|
Since short-term storage at room temperature of unfixed slides provided
the best results, this condition was tested for longer time with slides
fixed with formalin plus NP-40 at the time of immunostaining with the
PV pool of monoclonal antibodies and the IFA technique (Table
5). It was found that the number of
positive cells remained stable, i.e., not significantly different from the baseline value, for up to 30 days of storage. Then, it decreased progressively, dropping to zero positive cells after 75 days. The
relative proportion of weakly stained PMN progressively increased after
30 to 40 days of storage at room temperature, while in the meantime the
relative proportion of PMN stained at a moderate degree decreased.
View this table:
[in this window]
[in a new window]
|
TABLE 5.
Long-term effect of storage at room temperature of
unfixed cytospots on HCMV antigenemia assay sensitivity with the
PV pool
|
|
 |
DISCUSSION |
Some major conclusions can be drawn from this study: (i) a proper
positive control for the antigenemia assay is now available; (ii) it is
now feasible to prepare large batches of cytospots containing a
predetermined number of pp65-positive PMN; (iii) all parameters
involved in the performance of the assay can be carefully controlled,
thus allowing standardization of the test system for the first time;
(iv) quality control programs involving laboratories in different
countries and on different continents can be developed; and (v) unfixed
slides can be shipped at room temperature from a single reference
center for short-term staining or for long-term storage at
80°C
following fixation upon delivery.
Using in vitro-generated pp65-positive PMN, we have confirmed that
fixation with formalin provides better results than fixation methods
involving acetone, as previously reported by our group as well as by
others (1, 3, 8). The use of the formalin fixation procedure
without the subsequent permeabilization step has recently been
recommended because of its simplicity (8). On the basis of
this study, we believe that, although the suppression of the
permeabilization step does not cause a significant decrease in terms of
absolute number of positive cells, a more even distribution of specific
staining is obtained in permeabilized cells, while the time required
for test performance is only slightly longer (5 min).
As for the immunostaining technique, we previously reported
significantly better results given by the IFA compared to the IPA or
ABC procedure (3). We attributed this difference to the
procedure incorporating use of methanol-H2O2
for removal of endogenous peroxidase activity. However, when
3-amino-9-ethylcarbazole in acetate buffer was used for detection of
enzymatic activity (13, 15), no significant background
staining was encountered and no difference in terms of positive cells
was noted. In fact, no differences among IFA, IPA, and ABC were found
in this study.
All three commercially available pools of pp65-specific monoclonal
antibodies tested in this study were significantly less sensitive than
the PV pool. However, the Argene pool was found to possess a
significantly higher sensitivity than the Biotest pool, as already
reported (2), whereas no significant difference was observed
between the Argene and Chemicon or between the Chemicon and Biotest
pools. We believe that from this point on, use of in vitro-generated
pp65-positive PMN reference preparations will enable testing of new
pools of monoclonal antibodies and evaluation of their actual test performance.
One of the major objectives of this study was to comparatively evaluate
the optimal storage temperatures of fixed and unfixed slides. It was
shown that unfixed slides are best stored at room temperature for up to
1 month, while it was already known that fixed slides are best stored
at
80°C for unlimited periods. The optimal storage of unfixed
slides at room temperature for a reasonable period would allow shipment
at room temperature of cytospots to all over the world.
The newly developed procedure for in vitro preparation of cytospots
finally allows us to address the problem of long-term storage of large
batches of slides containing a predetermined number of pp65-positive
PMN. In fact, thus far, only the sensitivity of the antigenemia assay
for cytospin preparations from freshly collected blood samples has been
compared to the sensitivity achieved for preparations from blood
samples stored at room temperature or at 4°C for 24 to 72 h. In
this respect, several reports, although unanimously recognizing a
progressive loss in sensitivity of the antigenemia assay during
storage, have provided somewhat controversial findings (1, 6, 7,
10).
In conclusion, we believe that standardization protocols and quality
control programs may be developed for the HCMV antigenemia assay by
taking advantage of the novel procedure for generating pp65-positive
PMN in vitro.
 |
ACKNOWLEDGMENTS |
This work was partially supported by Ministero della
Sanità, Istituto Superiore di Sanità, X Progetto Nazionale
AIDS (1997) grant 50A-18, Progetto di Ricerca Finalizzata IRCCS
Policlinico San Matteo grant 820RFM95/01, and Policlinico San Matteo
Ricerca Corrente grant 820RCR96/01.
We thank Linda d'Arrigo for revision of the English and Gabriella
Garbagnoli and Teresa Pollini for technical assistance. We are grateful
to Franca Bordoni and Barbara Ferrara for typing the manuscript.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Servizio di
Virologia, IRCCS Policlinico San Matteo, 27100 Pavia, Italy. Phone:
39-382-502644/34. Fax: 39-382-502599. E-mail:
Virology{at}ipv36.unipv.it.
 |
REFERENCES |
| 1.
|
Boeckh, M.,
P. M. Woogerd,
T. Stevens-Ayers,
C. G. Ray, and R. A. Bowden.
1994.
Factors influencing detection of quantitative cytomegalovirus antigenemia.
J. Clin. Microbiol.
32:832-834[Abstract/Free Full Text].
|
| 2.
|
Brumback, B. G.,
S. N. Bolejack,
M. V. Morris,
C. Mohla, and T. E. Shutzbank.
1997.
Comparison of culture and the antigenemia assay for detection of cytomegalovirus in blood specimens submitted to a reference laboratory.
J. Clin. Microbiol.
35:1819-1821[Abstract].
|
| 3.
|
Gerna, G.,
M. G. Revello,
E. Percivalle, and F. Morini.
1992.
Comparison of different immunostaining techniques and monoclonal antibodies to the lower matrix phosphoprotein (pp65) for optimal quantification of human cytomegalovirus antigenemia.
J. Clin. Microbiol.
30:1232-1237[Abstract/Free Full Text].
|
| 4.
|
Grefte, J. M. M.,
B. T. F. van der Gun,
S. Schmolke,
M. van der Giessen,
W. J. van Son,
B. Plachter,
G. Jahn, and T. H. The.
1992.
The lower matrix protein pp65 is the principal viral antigen present in peripheral blood leukocytes during an active HCMV infection.
J. Gen. Virol.
73:2923-2932[Abstract/Free Full Text].
|
| 5.
|
Landry, M. L.,
D. Ferguson,
T. Stevens-Ayers,
M. W. A. Jonge, and M. Boeckh.
1996.
Evaluation of CMV Brite kit for detection of cytomegalovirus pp65 antigenemia in peripheral blood leukocytes by immunofluorescence.
J. Clin. Microbiol.
34:1337-1339[Abstract].
|
| 6.
|
Landry, M. L.,
D. Ferguson,
S. Cohen,
K. Huber, and P. Wetherill.
1995.
Effect of delayed specimen processing on cytomegalovirus antigenemia test results.
J. Clin. Microbiol.
33:257-259[Abstract].
|
| 7.
|
Niubò, J.,
J. L. Pérez,
A. Carrajal,
C. Ardanuy, and R. Martin.
1994.
Effect of delayed processing of blood samples on performance of cytomegalovirus antigenemia assay.
J. Clin. Microbiol.
32:1119-1120[Abstract/Free Full Text].
|
| 8.
|
Pérez, J. L.,
M. De Oña,
J. Niubò,
H. Villar,
S. Melón,
A. García, and R. Martín.
1995.
Comparison of several fixation methods for cytomegalovirus antigenemia assay.
J. Clin. Microbiol.
33:1646-1649[Abstract].
|
| 9.
|
Revello, M. G.,
E. Percivalle,
E. Arbustini,
R. Pardi,
S. Sozzani, and G. Gerna.
1998.
In vitro generation of human cytomegalovirus pp65 antigenemia, viremia and leukoDNAemia.
J. Clin. Investig.
101:2686-2692[Medline].
|
| 10.
|
Schäfer, P.,
W. Tenschert,
K. Gutensohn, and R. Laufs.
1997.
Minimal effect of delayed sample processing on results of quantitative PCR for cytomegalovirus DNA in leukocytes compared to results of an antigenemia assay.
J. Clin. Microbiol.
35:741-744[Abstract].
|
| 11.
|
Springer, T. A.
1994.
Traffic signals for lymphocyte recirculation and leukocyte emigration; the multistep paradigm.
Cell
76:301-314[Medline].
|
| 12.
|
The, T. H.,
A. P. van der Berg,
M. C. Harmsen,
W. van der Bij, and W. J. van Son.
1995.
The cytomegalovirus antigenemia assay: a plea for standardization.
Scand. J. Infect. Dis. Suppl.
99:25-29[Medline].
|
| 13.
|
van der Bij, W.,
J. Schirm,
R. Torensma,
W. J. van Son,
A. M. Tegzess, and T. H. The.
1988.
Comparison between viremia and antigenemia for detection of cytomegalovirus in blood.
J. Clin. Microbiol.
26:2531-2535[Abstract/Free Full Text].
|
| 14.
|
van der Bij, W.,
R. Torensma,
W. J. van Son,
J. Anema,
J. Schirm,
A. M. Tegzess, and T. H. The.
1988.
Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leukocytes.
J. Med. Virol.
25:179-188[Medline].
|
| 15.
|
van der Giessen, M.,
T. H. The, and W. J. van Son.
1991.
Cytomegalovirus antigenemia assay.
J. Clin. Microbiol.
29:2909-2910[Free Full Text]. (Letter.)
|
Journal of Clinical Microbiology, December 1998, p. 3585-3589, Vol. 36, No. 12
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Lilleri, D., Gerna, G., Furione, M., Bernardo, M. E., Giorgiani, G., Telli, S., Baldanti, F., Locatelli, F.
(2007). Use of a DNAemia cut-off for monitoring human cytomegalovirus infection reduces the number of preemptively treated children and young adults receiving hematopoietic stem-cell transplantation compared with qualitative pp65 antigenemia. Blood
110: 2757-2760
[Abstract]
[Full Text]
-
Revello, M. G., Gorini, G., Gerna, G.
(2004). Clinical Evaluation of a Chemiluminescence Immunoassay for Determination of Immunoglobulin G Avidity to Human Cytomegalovirus. CVI
11: 801-805
[Abstract]
[Full Text]
-
van der Strate, B. W. A., Hillebrands, J. L., Lycklama a Nijeholt, S. S., Beljaars, L., Bruggeman, C. A., van Luyn, M. J. A., Rozing, J., The, T. H., Meijer, D. K. F., Molema, G., Harmsen, M. C.
(2003). Dissemination of Rat Cytomegalovirus through Infected Granulocytes and Monocytes In Vitro and In Vivo. J. Virol.
77: 11274-11278
[Abstract]
[Full Text]
-
Nitsche, A., Oswald, O., Steuer, N., Schetelig, J., Radonic, A., Thulke, S., Siegert, W.
(2003). Quantitative Real-Time PCR Compared with pp65 Antigen Detection for Cytomegalovirus (CMV) in 1122 Blood Specimens from 77 Patients after Allogeneic Stem Cell Transplantation: Which Test Better Predicts CMV Disease Development?. Clin. Chem.
49: 1683-1685
[Full Text]
-
Gerna, G., Lilleri, D., Baldanti, F., Torsellini, M., Giorgiani, G., Zecca, M., De Stefano, P., Middeldorp, J., Locatelli, F., Revello, M. G.
(2003). Human cytomegalovirus immediate-early mRNAemia versus pp65 antigenemia for guiding pre-emptive therapy in children and young adults undergoing hematopoietic stem cell transplantation: a prospective, randomized, open-label trial. Blood
101: 5053-5060
[Abstract]
[Full Text]
-
Gerna, G., Percivalle, E., Sarasini, A., Baldanti, F., Campanini, G., Revello, M. G.
(2003). Rescue of human cytomegalovirus strain AD169 tropism for both leukocytes and human endothelial cells. J. Gen. Virol.
84: 1431-1436
[Abstract]
[Full Text]
-
Revello, M. G., Gerna, G.
(2002). Diagnosis and Management of Human Cytomegalovirus Infection in the Mother, Fetus, and Newborn Infant. Clin. Microbiol. Rev.
15: 680-715
[Abstract]
[Full Text]
-
Piiparinen, H., Hockerstedt, K., Lappalainen, M., Suni, J., Lautenschlager, I.
(2002). Monitoring of Viral Load by Quantitative Plasma PCR during Active Cytomegalovirus Infection of Individual Liver Transplant Patients. J. Clin. Microbiol.
40: 2945-2952
[Abstract]
[Full Text]
-
Gerna, G., Percivalle, E., Sarasini, A., Baldanti, F., Revello, M. G.
(2002). The attenuated Towne strain of human cytomegalovirus may revert to both endothelial cell tropism and leuko- (neutrophil- and monocyte-) tropism in vitro. J. Gen. Virol.
83: 1993-2000
[Abstract]
[Full Text]
-
Grazia Revello, M., Baldanti, F., Percivalle, E., Sarasini, A., De-Giuli, L., Genini, E., Lilleri, D., Labò, N., Gerna, G.
(2001). In vitro selection of human cytomegalovirus variants unable to transfer virus and virus products from infected cells to polymorphonuclear leukocytes and to grow in endothelial cells. J. Gen. Virol.
82: 1429-1438
[Abstract]
[Full Text]
-
Gerna, G., Percivalle, E., Baldanti, F., Sozzani, S., Lanzarini, P., Genini, E., Lilleri, D., Revello, M. G.
(2000). Human Cytomegalovirus Replicates Abortively in Polymorphonuclear Leukocytes after Transfer from Infected Endothelial Cells via Transient Microfusion Events. J. Virol.
74: 5629-5638
[Abstract]
[Full Text]
-
Gerna, G., Baldanti, F., Lilleri, D., Parea, M., Alessandrino, E., Pagani, A., Locatelli, F., Middeldorp, J., Revello, M. G.
(2000). Human Cytomegalovirus Immediate-Early mRNA Detection by Nucleic Acid Sequence-Based Amplification as a New Parameter for Preemptive Therapy in Bone Marrow Transplant Recipients. J. Clin. Microbiol.
38: 1845-1853
[Abstract]
[Full Text]